You are here: Industry Insights > CHB

News List

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication prnasia
January 11, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication.
AsSustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study prnasia
November 09, 2021
Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody...
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolim prnasia
July 28, 2021
Ascletis Pharma Inc. today announces the completion of 149 patient enrollment and the positive interim results of Phase IIb study on chronic hepatitis B (CHB) patients in China treated with ASC22 (Envafolimab) -- a first-in-class, subcutaneously ...
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax prnasia
July 20, 2021
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company has entered into a Cooperative Research and Development Agreement ...
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China prnasia
July 13, 2021
Ascletis Pharma Inc. today announces the dosing of the first cohort of healthy subjects in the ASC42 bridging study in China for CHB indication.
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication prnasia
June 07, 2021
Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for chronic hepatitis B (CHB) indication.
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study prnasia
December 04, 2020
Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ...